Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents

Inclusion Criteria: * Subjects free of obvious health-problems or with stable conditions * Male or female subject aged ≥5 to ≤18 years * Subject is living, studying, or working close to the study referral site * Parent or legal representative signed written informed consent; in addition for subjects ≥12 years: signed assent form Exclusion Criteria: * Prior history of rabies exposure or immunization (rabies vaccine and/or immune globulin) * Acute infection or disease within the last 2 weeks * History and/or family history of clinically significant immunodeficiency or auto-immune disease * Any history of known or suspected anaphylaxis or hypersensitivity reaction * Planned immunization with live vaccines during the next 3 months * Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational medicinal product